System L amino acid transporters mediate the movement of bulky neutral amino acids across cell membranes. Until now, three proteins that induce system L activity have been identified: LAT1, LAT2 and LAT3. The former two proteins belong to the solute carrier family 7 (SLC7), whereas the latter belongs to SLC43. In the present study, we present a new cDNA, designated LAT4, which also mediates system L activity when expressed in Xenopus laevis oocytes.
INTRODUCTION
System L is an ubiquitous plasma membrane amino acid transport system, that mediates sodium-independent transport of neutral amino acids (1).
It was first described in Ehrlich ascites tumor cells as a sodium-independent transport system for neutral amino acids that is specifically inhibited by a bicyclic amino acid, 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid (BCH) (1) (2) (3) (4) (5) .
Later, two subtypes for system L with distinct characteristics in substrate affinity, selectivity and transport properties were reported in primary hepatocytes and named systems L1 and L2 (5) .
To date, several transporters with system L characteristics have been identified at the molecular level. The first cloned transporters with system L activity were LAT1 and LAT2, which are members of the SLC (solute carrier) 7
family of transporters (6) (7) (8) (9) (10) (11) (12) (13) . They mediate sodium-independent amino acid exchange and recognise a wide range of large neutral amino acids as substrates (14) , expanding to small neutral amino acids in the case of LAT2 (8;10;11) . These proteins form heteromeric complexes via a disulfide bond with the heavy chain of 4F2 antigen (4F2hc, SLC3A2), a single transmembrane domain protein essential for the functional expression of LAT1 and LAT2 at the plasma membrane (8;11;12) .
In spite of the identification of heteromeric amino acid transporters LAT1 and LAT2, some of the previously reported properties of system L, mainly those of system L2, remained to be explained. Recently, LAT3 was identified by expression cloning from the hepatocarcinoma-derived cell line FLC4 (15) . LAT3
EXPERIMENTAL PROCEDURES
Computer Analysis-The nucleotide sequence homology search was performed using basic local alignment search tool (BLAST) via on-line connection to the National Center of Biotechnology Information. The BLASTn, program was run using default parameters. Multiple amino acid sequence comparisons were done with CLUSTALW via on-line connection to the European Bioinformatics Institute (EMBL-EBI). The prediction of transmembrane segments was performed with TopPred II. NETGLYC (http://www.cbs.dtu.dk/services/NetNGlyc/) and NETPHOS programs (http://www.cbs.dtu.dk/services/NetPhos/) were used for N-glycosylation and phosphorylation sites prediction. The phylogenetic tree was prepared from a multiple sequence alignment using Treetool (19) .
Molecular biology-The open reading frames (ORF) of mouse and human
LAT4, embryonic epithelial gene 1 (EEG1) (20) and LAT3 were obtained from Deutches Ressourcenzentrum für Genomforschung GmbH. NcoI and XhoI restriction sites were introduced, by PCR, at the ATG site and directly after the stop codon, respectively. The PCR product obtained was cloned in the vector pTLN (21) and sequenced. An HA tag was added after the first methionine of mouse LAT4 using standard molecular biology techniques. We used the human LAT4 cDNA as a template for site-directed mutagenesis (QuikChange TM ; Startagene) to replace serine 297 by alanine (LAT4SA). For HeLa cell studies, the cDNA was cloned into pCDNA3 (Invitrogen). All sequences in this study were performed in both directions with the Big Dye terminator V.3.1 cycle sequencing kit (Applied Biosystems). The reactions were analyzed with an Abi Prism 377 DNA sequencer.
Oocytes, injections, and transport measurements-Oocyte origin, handling, and injections were as described elsewhere (22) . Defolliculated stage VI X. laevis oocytes were injected with 25 ng/oocyte of human LAT4, human EEG1 or human LAT3 or with 10 ng each of 4F2hc and either Xenopus LAT1 or human LAT2 cRNA. cRNA was obtained using the mMessage mMachine TM kit (Ambion).
Influx rates of L-radio labelled amino acids (Amersham) were measured under linear conditions (10 minutes incubation) 2 days after cRNA injection. The uptake medium was choline chloride uptake solution (100 mM Choline chloride, 2 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM Hepes/Tris pH 7.5) containing the desired amino acid concentration and radioactive amino acid (10 µCi/ml for [ minutes. The loading ranged from 3000 to 10000 cpm/oocyte in non-injected or LAT4 injected oocytes, respectively. After loading, oocytes were washed 4 times in choline chloride uptake solution containing no amino acids. Efflux was then measured as tritium appearance in the incubation medium (500 µl), in the absence of amino acids or in the presence of phenylalanine (5 mM). To this end, aliquots (100 µl) were removed from the medium at distinct times and radioactivity was counted. Cell extraction and Western blot analysis-48 h after transfection, cells were harvested and membrane proteins were extracted using PBS-1% TX-100 containing protease inhibitors. Proteins were separated on 7.5% SDS polyacrylamide gels and electrotransferred (BioRad) to PVDF membranes. The membranes were blocked with 5% milk powder in PBS, and probed with the primary antibody 3F10 (Roche) at 4ºC by overnight incubation. Three washes in
RESULTS

Identification of LAT4
LAT3 has recently been identified as a new protein, previously known as POV1 (25) , that mediates low affinity system L amino acid transport activity (15) . LAT3 is expressed mainly in pancreas and liver, being nearly absent from kidney, brain or placenta. We hypothesized the existence of LAT3 homologue proteins that mediate this activity in these tissues. LAT3 shows a significant degree of identity (BLASTn) with two human cDNAs: the embryonic epithelial LAT4 presents a 57% identity to LAT3 and 30% identity to EGG1 (Fig.1a ). In addition, we have cloned mouse LAT4 (NM_173388). Mouse LAT4 is 91%
identical to human LAT4. Phylogenetic analyses indicated that LAT3, LAT4 and EEG1 belong to the same family (Fig. 1b) . LAT4 presents only about 10%
homology to other proteins with system L transport activity (LAT1 and LAT2) or to other members of the SLC7, SLC2 and SLC22 families of transporters.
The predicted topology (see under "Experimental Procedures") of these proteins indicates 12 transmembrane domains with both the N and C termini This broad mobility is indicative of glycosylation. In fact, treatment with EndoF reduces the molecular weight to ~66 kDa (Fig. 1d ).
Add here Figure 1 
Functional Characterization
To test the hypothesis that LAT4 is an amino acid transporter, we measured the uptake of isotopically labelled amino acids in oocytes injected with human LAT4 cRNA. An increased uptake of L-phenylalanine, L-leucine, Lisoleucine and L-methionine was observed when compared to non-injected oocytes ( Fig. 2a) . Mouse LAT4 and HA-tagged mouse LAT4 also induced Lphenylalanine transport when expressed in oocytes (data not shown). LAT4 mediated L-phenylalanine transport is not chloride-, sodium-nor pH-dependent ( Fig. 2b and c).
Add here Figure 2 We next performed kinetic analysis for the induced transport activity of Lphenylalanine ( Fig. 3 and Table I ) and L-leucine. Interestingly, and similar to LAT3 (15), the expression of LAT4 in oocytes leads to the presence of a transport activity with two kinetic components. The low affinity component has a
Km of 4694 ± 510 µM for L-phenylalanine and 3733 ± 1019 µM for L-leucine, and the high affinity component has a Km of 178 ± 29 µM for L-phenylalanine and 103 ± 62 µM for L-leucine.
Add here Figure 3 and Table I To further characterize the activity induced by LAT4, we measured the inhibition of sodium-independent L-phenylalanine uptake by distinct amino acids at a 200-fold excess concentration (100 µM versus 20 mM) (Fig. 4a ). Acidic and basic amino acids did not inhibit the transport. Small neutral amino acids were poor inhibitors for LAT4, except for L-cysteine which inhibited 45% of the entry of L-phenylalanine. In contrast, L-isoleucine, L-leucine, L-methionine and Lvaline were strong inhibitors (60-85% inhibition) of LAT4. The system L specific amino acid analog BCH also inhibited (70%) the entry of L-phenylalanine through LAT4. These data indicate that the activity induced by LAT4 corresponds to system L.
In addition, we analysed the substrate selectivity using amino acid analogs (Fig. 4a ). LAT4-induced activity is stereospecific since D-isomers of leucine, phenylalanine and valine are, by far, less efficient than the L-isomers in inhibiting L-phenylalanine transport. Similar to LAT3 (15), L-leucinol and Lvalinol, which have a hydroxymethyl group instead of a α-carboxyl group, also inhibit the uptake of L-phenylalanine. Methyl-tyrosine, a LAT1 specific inhibitor (27) , is a poor inhibitor of LAT4 (Fig. 4a ).
To further characterize the mechanism of transport, oocytes were loaded with L-phenylalanine (50 µM, 1 µCi/100 µl) for 1 hour, and the efflux of the labelled amino acid was measured by exposing the oocytes to the uptake solution with or without unlabelled substrate amino acid. The rate of efflux of the labelled amino acid was identical in the presence or absence of trans-amino acid (Fig. 4b) . This, together with the ion dependence data presented in Figure   2 , indicates that the transporter moves the substrate following its concentration gradient, therefore the transporter works through facilitated diffusion.
Add here Figure 4 NEM sensitivity of LAT4 kinetic components LAT3-induced transport activity has been shown to be sensitive to NEM (15) . We studied the sensitivity to NEM for the different LAT transporters (Fig.   5a ). CAT2, a system y+ transporter known to be very sensitive to NEM (28) was included as a positive control. LAT1 is almost insensitive to NEM, LAT2 and LAT4 show an intermediate sensitivity and LAT3 is the most severely affected system L transporter. To further characterize the effect of NEM on LAT4, the inhibition of the activity by NEM was monitored at different substrate concentrations (Fig.5b) . Interestingly, only the low affinity component was sensitive to NEM pre-treatment, resulting in a reduction of the Vm of transport (Table I) .
Babu et al. (15) suggested that phosphorylation may be involved in the kinetic behaviour of LAT3. Serine 297 in LAT4 is conserved in the three proteins of the family (Fig.1a) . This residue may be phosphorylated in vivo (NETPHOS program, (http://www.cbs.dtu.dk/services/NetPhos/)). We reasoned that mutation of this residue might have an impact on the activity of the protein.
Mutation of serine 297 to alanine resulted in a partial inhibition of the transport activity (see legend to Table I ). To further characterize this mutant, we evaluated the impact of NEM treatment on the activity of LAT4SA. Surprisingly, the activity of LAT4SA was insensitive to NEM at any substrate concentration (Fig 5c, Table I ). Therefore, replacement of LAT4 Ser297 for alanine renders the transporter resistant to NEM treatment.
Add here Figure 5 Tissue and subcellular distribution Add here Figure 6 RT-PCR analyses confirmed expression of LAT4 in PCT cells. LAT2 and LAT3 transcripts could not be detected, whereas the other known system L protein, LAT1, is also expressed in these cells (Fig.7a) . Next, we studied the (Fig 7b) . To study the high affinity component, we performed inhibition studies (Fig. 7c) . There is a basolateral L-phenylalanine transport activity that is not blocked by alanine, a typical LAT2 substrate, but it is almost completely inhibited by methyl-tyrosine, a LAT1 specific substrate, corroborating the RT-PCR data in Figure 7a . In all, these data indicate that the high affinity component corresponds mainly to LAT1. As shown in Figure 7d , NEM treatment results in inhibition of the low affinity component without affecting the high affinity component. This, together with the data in Figure 7a , suggests that the low affinity component corresponds mainly to LAT4.
Add here Figure 7
To study which cells in kidney and intestine express LAT4, we performed in situ hybridization analyses in paraffin embedded sections of these tissues derived from mice, and in human kidney sections (Fig. 8) . In the kidney, human ( (Fig. 8c) . No signals were detected using sense probes for human LAT4 in kidney (Fig. 8b) , or mouse LAT4 in intestine (Fig. 8d) , confirming the specificity of the results. induces amino acid transport activity in oocytes, however, we could not detect induction of any amino acid transport activity in EEG1-injected oocytes.
Additional experiments are required to demonstrate or rule out that EEG1 encodes a transporter for organic solutes.
LAT3 and LAT4 share many functional characteristics like sodium-, chloride-and pH-independence, narrow substrate specificity, a two-component kinetics, lack of trans-stimulation, stereo specificity, sensitivity to the amino acid analog BCH and they accept substitutions of the α-carboxyl group by an hydroxymethyl group in the transported substrates. However, the activities of these two transporters can be distinguished on the basis of NEM sensitivity.
While NEM strongly inhibits LAT3 activity ( (15), Fig.5a ), it only partially blocks that of LAT4. An unusual finding in this new family of transporters is the two-components kinetic behaviour. For LAT4, only the low affinity component is sensitive to NEM (Fig. 5b , Table I ). It has been suggested that phosphorylation might regulate the kinetic performance of LAT3 (15) . In the present study, we
show that mutation of a putative phosphorylation site conserved in the SLC43
family results in a transport activity resistant to NEM treatment (Fig.5c) Further research is needed to clarify this issue.
System L variants L1 (substrate affinity in the micromolar range and substantially inhibited by cysteine, valine, isoleucine, leucine, methionine, histidine, tryptophan, tyrosine, phenylalanine, and BCH) and L2 (substrate affinity in the millimolar range and narrower substrate selectivity) have been described previously (1) . These subtypes were reported in hepatoma cell lines and hepatocytes, respectively (5). An L3 subtype with an affinity between that of the L1 and L2 subtypes has been described in fibroblasts (31) . Uptake by system L2 is inhibited by isoleucine, leucine, phenylalanine, and BCH (5;32;33).
System L2 is sensitive to inhibition by NEM, whereas system L1 is not (32) .
While LAT1 fits the transport characteristics and the tissue distribution of subtype L1 (6), LAT3 coincides with the traits of L2 (15) . Due to the functional similarities to LAT3, LAT4 could contribute to L2 activity in some tissues.
The expression of LAT4 mRNA in PCT cells prompted the study of a LAT4-like activity in these cells. PCT cells can be grown on filters allowing the study of transporters at the basolateral and apical membranes separately. We have detected a LAT4-like activity at the basolateral membrane (Fig. 7) , that suggest a basolateral location for LAT4. Final demonstration requires the availability of an specific antibody. Due to its facilitative diffusion transport mechanism and its basolateral location, it is tempting to speculate that LAT4 might have an important role in the net flux of substrates from inside the cell to the exterior of the cell contributing to the transcellular flux of amino acids.
In the kidney, the absence of expression in the proximal tubule, where more than 90% of the reabsorption of amino acids occurs, rules out a major role of LAT4 in renal reabsorption of amino acids. Recycling of amino acids has been reported between Henle's loop and vasa recta in the juxtamedullary nephrons of the rat kidney (34) . This recycling could play a role in osmotic regulation at the initial stage of cellular adaptation (35) . LAT4 is expressed in distal tubules and collecting ducts where it could contribute to the basolateral fluxes of neutral amino acids between tubule epithelial cells and vasa recta during recycling (34) . In the intestine, LAT4 is mainly expressed in the crypts where it may play a role in the homeostasis of enterocytes. Moreover, high Km bulky neutral amino acid transport agencies have been detected in cerebral cortex (18) and astrocytes (36) . LAT4 mRNA was also detected in the brain (Fig.6) . It remains to be established whether LAT4 is responsible for these transport activities. 
